加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.65
−US$0.03 · -1.79%
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
前收盘价
US$1.65
−US$0.03 · -1.79%
盘后
US$1.65
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日内区间
当前US$1.65
52周区间
当前US$1.65
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
75
低估
情绪
55
多空交织
风险
53
风险偏高
动量
63
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日内区间
当前US$1.65
52周区间
当前US$1.65
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4980.3万 USD | 3108.1万 USD | 120.4万 USD | 13.9万 USD | 29.8万 USD |
| 销货成本 | 27.4万 USD | 61.6万 USD | 5897.2万 USD | 5251.6万 USD | 5504.6万 USD |
| 毛利 | 4952.9万 USD | 3046.5万 USD | −5776.8万 USD | −5237.7万 USD | −5474.8万 USD |
| 研究与开发 | 6112.1万 USD | 8448万 USD | 5888.7万 USD | 5281.6万 USD | 5504.6万 USD |
| 销售、一般及管理费用 | 3731.9万 USD | 1.32亿 USD | — | — | — |
| 营业费用 | 9844万 USD | 2.28亿 USD | 1.14亿 USD | 4838.3万 USD | 3234.2万 USD |
| 利息收入 | 690.9万 USD | 1229.3万 USD | 773.2万 USD | 159.6万 USD | 13.4万 USD |
| 利息支出 | 833.9万 USD | 1557.9万 USD | 1310.1万 USD | 278万 USD | 80.2万 USD |
| 折旧和摊销 | 62.1万 USD | 53.4万 USD | 55.4万 USD | 42.7万 USD | 29.2万 USD |
| 营业利润 | −4891.1万 USD | −1.97亿 USD | −1.72亿 USD | −1.01亿 USD | −8709万 USD |
| 净利润 | −5034.1万 USD | −2亿 USD | −1.77亿 USD | −1.02亿 USD | −8775.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 263.64%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2015年5月21日 | 1:7 | — | — |
已生效 2015年5月21日
1:7
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1593.82万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1001.51万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF590.81万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO354.12万0.03%139.17亿 USD0.24%US$353.71-0.86%
State Street SPDR S&P Pharmaceuticals ETFXPH339.27万0.74%4.69亿 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO322.24万0.02%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA184万0.01%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT145.19万0.01%220亿 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
